Design Therapeutics Inc at SVB Securities Global Biopharma Conference (Virtual) Transcript
Hello. Welcome to this fireside chat with Design Therapeutics. I'm pleased to be joined by Joao Siffert, Chief Executive Officer. Thanks for joining us today.
Thank you. Yeah, thanks for having us.
So it's an exciting time for the company. Wondering if you can start us off with a brief overview of your GeneTAC platform technology, the key pipeline programs you're pursuing, and what catalysts they'll have over the next -- the rest of the year.
Okay. Thanks, Joe. So we're a pioneering in a very exciting new platform of small molecules that we call Gene Targeted Chimeras or GeneTAC molecules for short. And these are molecules that are capable of targeting a specific gene and harness the person's own cell mechanisms to either dial up or to dial down gene expression without any need for irreversible
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
